Annovis Appoints Mark Guerin as Chief Financial Officer [Yahoo! Finance]
Traws Pharma, Inc. (TRAW)
Company Research
Source: Yahoo! Finance
the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development. Mr. Guerin has extensive experience and a successful track record in managing financial operations within biopharma companies. In 2013, he joined Onconova Therapeutics, now known as Traws Pharma, Inc. (Nasdaq: TRAW), to augment the company's financial reporting, forecasting, and internal controls following its IPO in July 2013, and was named its CFO in 2016. During his tenure as CFO, Onconova completed several critical financing transactions, including a rights offering, public offerings, registered direct offerings, and at-the-market offerings. Onconova merged with Trawsfynydd T
Show less
Read more
Impact Snapshot
Event Time:
TRAW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRAW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRAW alerts
High impacting Traws Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
TRAW
News
- Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
- Traws Pharma (NASDAQ:TRAW) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Traws Pharma GAAP EPS of -$0.34 [Seeking Alpha]Seeking Alpha
- Traws Pharma Reports Third Quarter 2025 Results and Business HighlightsGlobeNewswire
TRAW
Sec Filings
- 11/28/25 - Form 8-K
- 11/25/25 - Form 4
- 11/14/25 - Form SCHEDULE
- TRAW's page on the SEC website